

Updated: 3/6/25

Media and Letters on Concerns & Exemptions regarding Trump Tariffs

U.S. Health Care Associations

- [American Hospital Association \(AHA\)](#) – The AHA was a vocal advocate for tariff exemptions, particularly on medical equipment, drugs, and other essential healthcare supplies. They argued that tariffs on medical goods would result in higher costs for hospitals and ultimately affect patient care (4 Feb 2025).
- [Pharmaceutical Research and Manufacturers of America \(PhRMA\)](#) – PhRMA, which represents the pharmaceutical industry, requested tariff exemptions for drugs and medical products. They expressed concern that tariffs would increase the cost of medicines and negatively impact the healthcare system's ability to provide affordable treatments (4 Feb 2025).
- [Association for Accessible Medicines \(AAM\)](#) – The AAM, representing generic pharmaceuticals and biosimilars, raised concerns that tariffs could increase already problematic drug shortages and impose high costs on manufacturers (2 Feb 2025).
- [American Society of Health-System Pharmacists \(ASHP\)](#) – This group sought exemptions from medications and specific medication-related materials to prevent drug shortages and medication price increases (6 Feb 2025).
- [Consumer Healthcare Products Association \(CHPA\)](#) – This group sought exemptions for healthcare products that will raise costs on American consumers, limit access to affordable self-care, and disrupt global supply chains (3 Feb 2025).
- [Healthcare Distribution Alliance \(HDA\)](#) – A statement from the Healthcare Distribution Alliance (HDA), which represents pharmaceutical distributors in the US, stated that tariffs on pharmaceuticals could strain the US pharmaceutical supply chain and urged the Trump Administration to exempt pharmaceuticals from the tariffs (5 Feb 2025).
- [Health Industry Distributors Association \(HIDA\)](#) – HIDA, representing medical distributors, sought exemptions on medical supplies and products. They expressed concerns that tariffs would increase operational costs and limit the availability of critical healthcare items.

International

- [BVMed](#) – The German Medical Technology Association (BVMed) issued a [letter](#) to the German Chancellery calling for medical devices to be exempted from planned tariff initiatives or other trade-restricting measures (19 Feb 2025).
- [GMTA](#) shared a [template letter](#) amongst its medtech association members for aligned advocacy with their respective governments urging the exemption of the medtech sector from tariffs and potential retaliatory measures (11 Feb 2025).

- **MedTech Canada** – Issued a [joint letter](#) with AdvaMed to Doug Ford, Premier of Ontario and Chair of the Canadian Council of the Federation representing all Canadian provinces and territories emphasizing the importance of medtech to the Canadian and U.S. health systems and supply chains, urging the exemption of the medtech sector from any potential Canadian retaliatory measures (31 Jan 2025).
- **MedTech Canada** – Also issued a [letter](#) to Dominic LeBlanc, Canadian Minister of Finance and Intergovernmental Affairs urging the exemption of the medtech sector from any potential Canadian federal retaliatory measures given the negative financial impact likely to result due to the integrated nature of the North American medtech ecosystem (21 Jan 2025).
- **MedTech Europe** and **COCIR** issued a joint letter to the EU Trade Commissioner to urge the EU, in its current deliberations on countermeasures that could be imposed in response to US tariffs, to refrain from imposing tariffs on imports of any medical technologies, including IVDs. The request extended to inputs for these products, including raw materials, accessories, spare parts and various other essential components thereof. It was noted in the letter that using such tariffs as a potential retaliatory strategy to counteract US trade policy measures, such as the recently announced tariffs on imports of steel and aluminum into the US or US reciprocal tariff policy, could disrupt access to medical technologies in the EU (17 Feb 2025).
- AdvaMed issued a joint letter ([English](#) / [Spanish](#)) with the **[Mexican Association of the Innovative Medical Device Industry \(AMID\)](#)**, **[Baja’s Medical Device Cluster](#)**, **[BIO El Paso - Juarez](#)** and the **[Mexican National Council of the Maquiladora and Export Manufacturing Industry \(INDEX USA\)](#)** to Mexican Minister of Economy Marcelo Ebrard emphasizing the importance of medtech to the U.S.-Mexican health systems and supply chains, urging the exemption of the medtech sector from tariffs and any potential retaliatory measures (6 Mar 2025).